Oruka Therapeutics, Inc. (NASDAQ:ORKA) has 182 institutional investors that have filed 13F reports for the period ending March 2026.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| FMR LLC | 31 Mar, 2026 | 7,431,403 | 170,019 | 2.34% | $364,510,318.00 |
| Venrock Adviser, LLC | 31 Mar, 2026 | 4,148,428 | 0 | 0.00% | $203,480,393.00 |
| Fairmount Funds Management LLC | 31 Mar, 2026 | 3,705,262 | 0 | 0.00% | $181,743,101.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 3,527,087 | -12,328 | -0.35% | $173,003,617.00 |
| VIKING GLOBAL INVESTORS LP | 31 Mar, 2026 | 2,666,690 | 0 | 0.00% | $130,801,145.00 |
| Paradigm Biocapital Advisors LP | 31 Mar, 2026 | 2,320,316 | 610,000 | 35.67% | $113,811,500.00 |
| RTW INVESTMENTS, LP | 31 Mar, 2026 | 2,058,148 | 0 | 0.00% | $100,952,159.00 |
| Deep Track Capital, LP | 31 Mar, 2026 | 2,034,203 | -127,307 | -5.89% | $99,777,657.00 |
| Remedium Capital Partners, LLC | 31 Mar, 2026 | 1,889,115 | 336,701 | 21.69% | $92,661,091.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 1,859,631 | 1,859,631 | 0.00% | $91,214,901.00 |
| State Street Corp | 31 Mar, 2026 | 1,613,461 | 229,614 | 16.59% | $79,140,262.00 |
| PERCEPTIVE ADVISORS LLC | 31 Mar, 2026 | 1,395,501 | -81,000 | -5.49% | $68,449,324.00 |
| Polar Capital Holdings Plc | 31 Mar, 2026 | 1,047,693 | 69,405 | 7.09% | $51,389,342.00 |
| CITADEL ADVISORS LLC | 31 Mar, 2026 | 1,007,537 | 281,419 | 38.76% | $49,419,690.00 |
| Franklin Resources Inc | 31 Mar, 2026 | 1,004,056 | 65,635 | 6.99% | $49,248,948.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Mar, 2026 | 954,867 | 12,360 | 1.31% | $46,848,119.00 |
| MERCER GLOBAL ADVISORS INC /ADV | 31 Mar, 2026 | 802,470 | 57,193 | 7.67% | $39,361,154.00 |
| Avidity Partners Management LP | 31 Mar, 2026 | 760,424 | 100,000 | 15.14% | $52,020,606.00 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 31 Mar, 2026 | 727,449 | 727,449 | 0.00% | $35,682.00 |
| Woodline Partners LP | 31 Mar, 2026 | 574,882 | 329 | 0.06% | $28,197,962.00 |